Bioanalytical strategies for PK analysis of antibody–drug conjugate therapeutics using LC–HRMS & LC–MS/MS

Antibody–drug conjugates (ADCs) combine the best of two modalities: toxin efficacy and antibody specificity. The result is an improved therapeutic window with fewer side effects. However, the bioanalytical requirements for PK analysis also require a multifaceted approach. Herein we describe various mass spectrometry-based strategies Frontage has successfully applied in the bioanalysis of ADCs for clinical and preclinical studies.

BZ ITZ Frontage ADC-01-min